This paper describes a proof-of-concept validation of a dry powder human papillomavirus (HPV) respirable vaccine developed using a particle engineering approach. A key characteristic of the developed formulation is the application of glucopyranosyl lipid A (GLA) to the surface of vaccine particles to simultaneously improve aerosolization performance and recognition by the lung immune cells. Extensive in vitro characterization of the resulting formulation was carried out along with in vivo tests to determine lung deposition behavior, following intratracheal administration to mice. A subsequent short-term immunization study provided evidence of an immune response comparable to that achieved via subcutaneous delivery.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest

Low GWP pMDI Q&A with Aptar’s ZEN30 Futurity™ Valve Solution
Publications, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Sustainability, Drug Delivery Innovations

Innovations in Pulmonary Care: DPI and NPLI Lead the Way
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Market Insights, Product Solutions

Spotlight on Emissions Reductions for A Lower CO2 Footprint in Pharmaceutical Packagi...
Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Advanced Analysis of Dry Powder Inhaler Formulations for Bioequivalence
Publications, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations